Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder

Acta Paediatrica, International Journal of Paediatrics

Volumn 102, Issue 5, 2013, Pages 462-470

  Wijburg, Frits A ^a   Wȩgrzyn, Grzegorz ^b   Burton, Barbara K ^c   Tylki Szymańska, Anna ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GDA SK   (Poland)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Attention deficit hyperactivity disorder; Autism spectrum disorder; Developmental disabilities; Mucopolysaccharidosis type III; Speech language disorders

Indexed keywords

ISOFLAVONE;

ATTENTION DEFICIT DISORDER; AUTISM; CLINICAL FEATURE; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DIAGNOSTIC ERROR; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME ACTIVITY; GENETIC ANALYSIS; HUMAN; IDIOPATHIC DISEASE; LABORATORY TEST; PATIENT REFERRAL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SANFILIPPO SYNDROME; SPEECH DISORDER;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL MARKERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DEVELOPMENTAL DISABILITIES; DIAGNOSTIC ERRORS; HUMANS; MUCOPOLYSACCHARIDOSIS III;

EID: 84876147561     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12169     Document Type: Review

References (60)

1. Neufeld EF, Muenzer J,. The mucopolysaccharidoses. In:, Scriver CR, ed. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF,. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-54.
3. Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA,. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008; 31: 240-52.
4. Ruijter GJ, Valstar MJ, van de Kamp JM, van der Helm RM, Durand S, van Diggelen OP, et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 2008; 93: 104-11.
5. Valstar MJ, Bruggenwirth HT, Olmer R, Wevers RA, Verheijen FW, Poorthuis BJ, et al. Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis 2010; 33: 759-67.
6. Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJ, Wevers RA, et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 2010; 68: 876-87.
7. Valstar MJ, Bertoli-Avella AM, Wessels MW, Ruijter GJ, de Graaf B, Olmer R, et al. Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations. Hum Mutat 2010; 31: E1348-60.
8. de Ruijter J, Valstar MJ, Wijburg FA,. Mucopolysaccharidosis type III (Sanfilippo syndrome): emerging treatment strategies. Curr Pharm Biotechnol 2011; 12: 923-30.
9. van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA,. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 1981; 20: 152-60.
10. Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA,. Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet J Rare Dis 2011; 6: 43.
11. Malm G, Mansson JE,. Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Paediatr 2010; 99: 1253-7.
12. Meyer A, Kossow K, Gal A, Muhlhausen C, Ullrich K, Braulke T, et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 2007; 120: e1255-61.
13. Moog U, van Mierlo I, van Schrojenstein Lantman-de Valk HM, Spaapen L, Maaskant MA, Curfs LM,. Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems? Am J Med Genet C Semin Med Genet 2007; 145C: 293-301.
14. Moog U,. Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia. (Invited comment). Acta Psychiatr Scand 2010; 122: 166.
15. Heron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C, et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A 2011; 155A: 58-68.
16. Bax MC, Colville GA,. Behaviour in mucopolysaccharide disorders. Arch Dis Child 1995; 73: 77-81.
17. Fraser J, Wraith JE, Delatycki MB,. Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin Genet 2002; 62: 418-21.
18. White KK, Karol LA, White DR, Hale S,. Musculoskeletal manifestations of Sanfilippo syndrome (mucopolysaccharidosis type III). J Pediatr Orthop 2011; 31: 594-8.
19. Andrade F, Prieto JA, Elorz J, Martin S, Sanjurjo P, Aldamiz-Echevarria L,. Stability of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Clin Chim Acta 2008; 388: 73-7.
20. de Jong JG, Hasselman JJ, van Landeghem AA, Vader HL, Wevers RA,. The spot test is not a reliable screening procedure for mucopolysaccharidoses. Clin Chem 1991; 37: 572-5.
21. Mabe P, Valiente A, Soto V, Cornejo V, Raimann E,. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin Chim Acta 2004; 345: 135-40.
22. Byers S, Rozaklis T, Brumfield LK, Ranieri E, Hopwood JJ,. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. Mol Genet Metab 1998; 65: 282-90.
23. Chih-Kuang C, Shuan-Pei L, Shyue-Jye L, Tuen-Jen W,. MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in Sanfilippo and Morquio syndromes. J Clin Lab Anal 2002; 16: 253-8.
24. Gray G, Claridge P, Jenkinson L, Green A,. Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses: an evaluation. Ann Clin Biochem 2007; 44: 360-3.
25. Mahalingam K, Janani S, Priya S, Elango EM, Sundari RM,. Diagnosis of mucopolysaccharidoses: how to avoid false positives and false negatives. Ind J Pediatr 2004; 71: 29-32.
26. Auray-Blais C, Bherer P, Gagnon R, Young SP, Zhang HH, An Y, et al. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab 2011; 102: 49-56.
27. Auray-Blais C, Lavoie P, Zhang H, R, Clarke JT, Maranda B, et al. An improved method for glycosaminoglycan analysis by LC-MS/MS of urine samples collected on filter paper. Clin Chim Acta 2012; 413: 771-8.
28. Martell LA, Cunico RL, Ohh J, Fulkerson W, Furneaux R, Foehr ED,. Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis 2011; 3: 1855-66.
29. Nielsen TC, Rozek T, Hopwood JJ, Fuller M,. Determination of urinary oligosaccharides by high-performance liquid chromatography/electrospray ionization-tandem mass spectrometry: application to Hunter syndrome. Anal Biochem 2010; 402: 113-20.
30. Marsh J, Fensom AH,. 4-Methylumbelliferyl alpha-N-acetylglucosaminidase activity for diagnosis of Sanfilippo B disease. Clin Genet 1985; 27: 258-62.
31. Voznyi Ya V, Karpova EA, Dudukina TV, Tsvetkova IV, Boer AM, Janse HC, et al. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease C (MPS III C). J Inherit Metab Dis 1993; 16: 465-72.
32. Karpova EA, Voznyi Ya V, Keulemans JL, Hoogeveen AT, Winchester B, Tsvetkova IV, et al. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA). J Inherit Metab Dis 1996; 19: 278-85.
33. He W, Voznyi Ya V, Boer AM, Kleijer WJ, van Diggelen OP,. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type D (MPS IIID). J Inherit Metab Dis 1993; 16: 935-41.
34. Kleijer WJ, Karpova EA, Geilen GC, Keulemans JL, Huijmans JG, Tsvetkova IV, et al. Prenatal diagnosis of Sanfilippo A syndrome: experience in 35 pregnancies at risk and the use of a new fluorogenic substrate for the heparin sulphamidase assay. Prenat Diagn 1996; 16: 829-35.
35. Hopwood JJ,. Prenatal diagnosis of Sanfilippo syndrome. Prenat Diagn 2005; 25: 148-50.
36. Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B,. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease-lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim Biophys Acta 2009; 1793: 710-25.
37. Vance JM, Conneally PM, Wappner RS, Yu PL, Brandt IK, Pericak-Vance MA,. Carrier detection in Sanfilippo syndrome type B: report of six families. Clin Genet 1981; 20: 135-40.
38. Fuller M, Tucker JN, Lang DL, Dean CJ, Fietz MJ, Meikle PJ, et al. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet 2011; 48: 422-5.
39. Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, Wegrzyn G,. Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr 2009; 98: 743-9.
40. Altarescu G, Renbaum P, Eldar-Geva T, Brooks B, Varshaver I, Avitzour M, et al. Preventing mucopolysaccharidosis type II (Hunter syndrome): PGD and establishing a Hunter (46, XX) stem cell line. Prenat Diagn 2011; 31: 853-60.
41. Tomi D, Schultze-Mosgau A, Eckhold J, Schopper B, Al-Hasani S, Steglich C, et al. First pregnancy and life after preimplantation genetic diagnosis by polar body analysis for mucopolysaccharidosis type I. Reprod Biomed Online 2006; 12: 215-20.
42. Qubbaj W, Al-Aqeel AI, Al-Hassnan Z, Al-Duraihim A, Awartani K, Al-Rejjal R, et al. Preimplantation genetic diagnosis of Morquio disease. Prenat Diagn 2008; 28: 900-3.
43. de Ru MH, Bouwman MG, Wijburg FA, van Zwieten MC,. Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening. Mol Genet Metab 2012; 107: 501-7.
44. Fletcher J, Wilcken B,. Neonatal screening for lysosomal storage disorders. Lancet 2012; 379: 294-5.
45. The human gene mutation database. Cardiff: Institute of Medical Genetics in Cardiff, Cardiff University. Available at from URL http://www.hgmd.cf.ac.uk/ ac/index.php. (accessed on August 2, 2012).
46. Yogalingam G, Hopwood JJ,. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications. Hum Mutat 2001; 18: 264-81.
47. Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 2003; 31: 1105-17.
48. Yamada Y, Kato K, Sukegawa K, Tomatsu S, Fukuda S, Emura S, et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant 1998; 21: 629-34.
49. Herskhovitz E, Young E, Rainer J, Hall CM, Lidchi V, Chong K, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis 1999; 22: 50-62.
50. Sivakumur P, Wraith JE,. Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis 1999; 22: 849-50.
51. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 1995; 345: 1398-402.
52. Sanberg PR, Eve DJ, Willing AE, Garbuzova-Davis S, Tan J, Sanberg CD, et al. The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells. Cell Transplant 2011; 20: 85-94.
53. Dickson PI, Chen AH,. Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. Curr Pharm Biotechnol 2011; 12: 946-55.
54. Tsai TH,. Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 2005; 1073: 317-22.
55. Guffon N, Bin-Dorel S, Decullier E, Paillet C, Guitton J, Fouilhoux A,. Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. J Pediatr 2011; 159: 838-44.e1.
56. Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE 2010; 5: e14192.
57. Delgadillo V, O'Callaghan MM, Artuch R, Montero R, Pineda M,. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 2011; 34: 1039-44.
58. Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A, Tylki-Szymanska A, Puk E, Liberek A, et al. Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 2011; 17: CR196-202.
59. de Ruijter J, Valstar MJ, Narajczyk M, Wegrzyn G, Kulik W, Ijlst L, et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012; 71: 110-20.
60. Wȩgrzyn A,. Gene expression-targeted isoflavone therapy. IUBMB Life 2012; 64: 307-15.